Summary
Pyrazine diazohydroxide (sodium salt, NSC 361456; PZDH) is a new antitumor drug with relatively broad activity in initial evaluations against murine leukemias, solid tumors, and two human tumor xenograftsin vivo. The present studies were designed to address questions about PZDH activity on different treatment schedules, its activity against metastases, and the extent of its cross-resistance with established drugs. Human LOX amelanotic melanoma xenografts in athymic mice were used to explore schedule dependence and activity against natural metastases, and a series of drug-resistant murine leukemais provided anin vivo cross-resistance profile. Singledose treatment and prolonged treatment provided equivalent therapeutic responses to PZDH by both the i. p. and i.v. routes in the i.p. LOX model. A s.c. LOX model resulting in spontaneous pulmonary metastases was adapted for bioassay and quantitation of the numbers of LOX cells killed by PZDH among both primary and metastatic cell populations. It was demonstrated that PZDH afforded about 2-log10 orders of magnitude greater cell kill among pulmonary metastases than against primary s.c. LOX tumors in the same mouse. Murine leukemias resistant to doxorubicin (ADR), vincristine (VCR), cisplatin (DDPt), methotrexate (MTX),N,N′-bis(2-chloroethyl)-N-nitrosourea (BCNU), and cyclophosphamide (CPA) were not cross-resistant to PZDH. However, both P388 and L1210 leukemia sublines resistant to melphalan (l-PAM) were cross-resistant to PZDH, suggesting that patients previously treated withl-PAM might have less likelihood of response to PZDH than those who had had no opportunity to developl-PAM resistance. Although these observations should not be applied to clinical studies without due caution, they support clinical evaluation of PZDH as well as continued investigation of its molecular pharmacology.
Similar content being viewed by others
References
Baker DC, Hand ES, Plowman J, Rampal JB, Safavy A, Haugwitz RD, Narayanan VL (1987) Synthesis, chemical stability, and preclinical antitumor activity of pyrazine diazohydroxide, sodium salt (NSC 361456). Anti-Cancer Drug Des 2: 297–309
Brodfuehrer JI, Moore DJ, Melder DC, Wilke TJ, Powis G (1988)In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation. Invest New Drugs 6:3–9
Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute (1984)In vivo cancer models 1976–1982. U.S. Government Printing Office, NIH Publication 84-2635
DeVita VT Jr, Hubbard SM, Longo DL (1987) The chemotherapy of lymphomas: looking back, moving forward — the Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 47:5810
Dykes DJ, Shoemaker RH, Harrison SD Jr, Laster WR Jr, Griswold DP Jr, Mayo JG, Abbott BJ, Fine DL, Fodstad O, Boyd MR (1987) Development and therapeutic response of a spontaneous metastasis model of a human melanoma (LOX) in athymic mice. Proc Am Assoc Cancer Res 28:431
Fidler IJ (1986) Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 5:29–49
Fodstad O, Aamdal S, Pihl A, Boyd MR (1985) Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas. Cancer Res 45:1778–1786
Harrison SD Jr, Brockman RW, Trader MW, Laster WR Jr, Griswold DP Jr (1987) Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894)in vivo. Invest New Drugs 5:345–351
Harrison SD Jr, Dykes DJ, Plowman J, Griswold DP Jr (1988) Schedule dependence, antimetastasis activity, and cross-resistance of pyrazine diazohydroxide in murine models and human tumor xenografts. Proc Am Assoc Cancer Res 29:323
Hryniuk WM (1987) Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14 (1):65–74
Lloyd HH (1977) Application of tumor models toward the design of treatment schedules for cancer chemotherapy. In: Drewinko B, Humphrey RM (eds) Growth kinetics and biochemical regulation of normal and malignant cells. Williams & Wilkins, Baltimore, pp 455–469
Moore DJ, Brodfuehrer JI, Wilke TJ, Powis G (1988) Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog. Cancer Chemother Pharmacol 21:269–273
Plowman J, Haugwitz RD, Narayanan VL, Baker DC, Hand ES, Rampal JB, Safavy A (1986) Preclinical antitumor activity of pyrazine diazohydroxide, NSC 361456. Proc Am Assoc Cancer Res 27:275
Schabel FM Jr, Griswold DP Jr, Laster WR Jr, Corbett TH, Lloyd HH (1977) Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther 1:411–435
Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH (1983) Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67:905–922 (see correction, Cancer Treat Rep 68: 453–459)
Shoemaker R, Wolpert-DeFilippes M, Mayo J, Abbott B, Plowman J, Venditti J, Ovejera A, Donovan P, Griswold D, Dykes D, Boyd M, Fodstad O (1985) Experimental chemotherapy studies of a human melanoma in athymic mice using a survical endpoint. Proc Am Assoc Cancer Res 26:330
Skipper HE (1987) Some principles which seem important in the design of chemotherapy to be used alone or in an adjuvant setting. 1987 Jeffrey A Gottlieb Memorial Award lecture. 31 st Annual Clinical Conference on Recent Advances in Systemic Therapy of Genitourinary Malignancies. MD Anderson Hospital and Tumor Institute, Houston, Texas
Skipper HE (1989) On the design of combination chemotherapy regimens to be used alone or in an adjuvant setting. Proceedings of the 2nd International Congress on Neo-Adjuvant Chemotherapy. Colloque Inserm-John Libbey Series, Paris (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harrison, S.D., Plowman, J., Dykes, D.J. et al. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo. Cancer Chemother. Pharmacol. 25, 425–429 (1990). https://doi.org/10.1007/BF00686053
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686053